{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:51:19Z","timestamp":1760298679353},"reference-count":10,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T00:00:00Z","timestamp":1361923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2013,10]]},"abstract":"Background<\/jats:title>Cytology laboratories in the UK<\/jats:styled-content> routinely treat unsatisfactory cervical liquid\u2010based cytology (LBC<\/jats:styled-content>) specimens with glacial acetic acid (GAA<\/jats:styled-content>) to reduce the unsatisfactory rate. However, there is limited published data on the effect of GAA<\/jats:styled-content> reprocessing on the molecular detection of human papillomavirus (HPV<\/jats:styled-content>). The aim of this study was to assess the impact of GAA<\/jats:styled-content> treatment of cervical ThinPrep\u00ae<\/jats:sup> samples on HPV<\/jats:styled-content> detection with the cobas\u00ae<\/jats:sup> 4800 HPV<\/jats:styled-content> Test (Roche Molecular Systems, Pleasanton, CA<\/jats:styled-content>, USA).<\/jats:p><\/jats:sec>Methods<\/jats:title>Residual ThinPrep samples (n<\/jats:italic>\u00a0=\u00a0121) were selected to provide a range of typical cytology results and enrich the study samples for HPV<\/jats:styled-content> positivity. Specimens were equally split into two fractions: one part treated with 10% GAA<\/jats:styled-content> and the other part left untreated. All samples were HPV<\/jats:styled-content> tested using the cobas 4800 HPV<\/jats:styled-content> Test, which simultaneously detects a total of 14 high\u2010risk HPV<\/jats:styled-content> (hrHPV<\/jats:styled-content>) genotypes and individually identifies HPV<\/jats:styled-content>16 and HPV<\/jats:styled-content>18. The HPV<\/jats:styled-content> positive\/negative status of tested samples determined the level of agreement between treated and untreated fractions; one sample failed owing to detection of a clot by the instrument during pipetting, leaving 120 samples in the study. Statistical analysis was performed using an unweighted kappa.<\/jats:p><\/jats:sec>Results<\/jats:title>Analysis of overall HPV<\/jats:styled-content> positivity showed 97.5% (117\/120) agreement between the treated and untreated fractions with a kappa value of 0.95. There were 63\/65 (96.9%) concordant HPV<\/jats:styled-content> positive and 54\/55 (98.2%) concordant HPV<\/jats:styled-content> negative results. In addition to the three discordant results for overall HPV<\/jats:styled-content> positivity, there were three HPV<\/jats:styled-content> type\u2010specific discrepancies giving a total of 114\/120 concordant HPV<\/jats:styled-content> results (95% agreement).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Glacial acetic acid (GAA<\/jats:styled-content>) treatment of cervical ThinPrep specimens does not have significant adverse affects on HPV<\/jats:styled-content> detection with the cobas 4800 HPV<\/jats:styled-content> Test.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cyt.12052","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T20:32:52Z","timestamp":1362083572000},"page":"321-326","source":"Crossref","is-referenced-by-count":8,"title":["Effect of glacial acetic acid treatment of cervical ThinPrep specimens on HPV DNA<\/scp> detection with the cobas 4800 HPV<\/scp> test"],"prefix":"10.1111","volume":"24","author":[{"given":"M.","family":"McMenamin","sequence":"first","affiliation":[{"name":"Cytopathology Department Altnagelvin Hospital Western Health and Social Care Trust Derry Northern Ireland UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"McKenna","sequence":"additional","affiliation":[{"name":"Cytopathology Department Altnagelvin Hospital Western Health and Social Care Trust Derry Northern Ireland UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,27]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"MossSM GrayA MarteauTet\u00a0al.Evaluation of HPV\/LBC Cervical Screening Pilot Studies: Report to the Department of Health. (Revised October 2004).Sheffield:NHSCSP; 2004. Available at:http:\/\/www.cancerscreening.nhs.uk\/cervical\/evaluation-hpv-2006feb.pdf(Accessed 23 January 2013)."},{"key":"e_1_2_6_3_1","unstructured":"Northern Ireland Cervical Screening Programme. Annual Report and Statistical Bulletin 2009\u20132010.Belfast:Quality Assurance Reference Centre;2010."},{"key":"e_1_2_6_4_1","unstructured":"The NHS Information Centre Screening and Immunisation Team.NHSCSP Statistical Bulletin England 2010\u20132011.Sheffield:NHSCSP;2011. Available at:http:\/\/www.cancerscreening.nhs.uk\/cervical\/cervical-statistics-bulletin-2010-11.pdf(Accessed 23 January 2013)."},{"key":"e_1_2_6_5_1","unstructured":"Cervical Screening Wales.A Report on the Implementation of Liquid Based Cytology in Wales: July 2004\u2013December 2005.Cardiff:Cervical Screening Wales;2007. Available at:http:\/\/www.screeningservices.org.uk\/csw\/prof\/docs\/lbc_report.pdf(Accessed 23 January 2013)"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06719-11"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1309\/GE86-156K-EGM2-DGXB"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21349"},{"key":"e_1_2_6_9_1","unstructured":"NHS Cancer Screening Programmes.Achievable standards Benchmarks for reporting and Criteria for evaluating cervical cytopathology.3rd edn. NHS CSP Publication No 1.Sheffield:NHSCSP;2012. Available at:http:\/\/www.cancerscreening.nhs.uk\/cervical\/publications\/nhscsp01.pdf(Accessed 13 January 2013)."},{"volume-title":"ThinPrep 3000 Processor Operator's Manual","year":"2000","author":"Cytyc (Hologic)","key":"e_1_2_6_10_1"},{"volume-title":"cobas\u00ae 4800 HPV Test package insert Doc Rev 2.0","year":"2010","author":"Roche","key":"e_1_2_6_11_1"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcyt.12052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.12052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:21:19Z","timestamp":1696281679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cyt.12052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,27]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/cyt.12052"],"URL":"https:\/\/doi.org\/10.1111\/cyt.12052","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"type":"print","value":"0956-5507"},{"type":"electronic","value":"1365-2303"}],"subject":[],"published":{"date-parts":[[2013,2,27]]}}}